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What to do about poor clinical performance in
clinical trials
Su Mason, Jon Nicholl, Richard Lilford
The performance of individual clinicians is being monitored as never before. Su Mason and colleagues
discuss the implications of this for clinical trials and recommend what should happen if during a trial
the performance of one clinician or one centre is identified as being particularly poor. Tom Treasure, a
surgeon, wants the monitoring to be done fairly and to take account of the complexities of clinical
practice; and Heather Goodare, a patient, wants to be told when things go wrong.
The Department of Health in England has issued guide›
lines for research governance stating that healthcare
organisations remain responsible for the quality of all
aspects of patients’ care whether or not some aspects of
the care are part of a research study.1 We discuss how this
obligation can be met in multicentre trials, given that
data on the performance of clinicians are held by the
trial management team, not by the host organisation.
Should we monitor, and who should
do it?
If neither the host organisation, nor the trial team,
takes responsibility for monitoring performance then
patients are left with no protection against substandard
practice.2 We are aware of the dangers of applying a
higher standard of scrutiny to clinical trials than to
routine practice, but clinical trials often involve a
relatively new treatment (such as an innovative surgical
operation) where outcomes vary by skill.3 4 With any
new treatment it is appropriate to scrutinise
outcomes—whether or not the treatment is part of a
comparative study. But in a clinical trial who should be
responsible for statistical monitoring of outcomes?
Three possibilities arise:
x Both the healthcare organisations and the trial team
could collect and monitor performance data, but this is
likely to lead to confusion of responsibility and a waste
of effort.
x Healthcare organisations could be required to
collect and monitor outcomes independently of the
trial, but they would have, at best, limited access to the
comparative data. It would thus be hard to judge
whether, say, a 5% rate of blood transfusion was too
high. This applies especially to new technologies where
good quality data for comparison do not (yet) exist.
x The trial statistician responsible for analysing data for
interim monitoring could scrutinise outcome by
clinician or organisation at little extra effort. We suggest
that this is the best option and fits with the concept of
“tracker trials.”5 This is the idea that a trial is not simply a
randomised comparison of two generic treatment
methods but also an observational comparison of
subcategories of treatment (such as different devices and
different centres or clinicians). Thus, under our proposal,
healthcare organisations would discharge part of their
responsibility for patient welfare during a trial by explic›
itly giving responsibility for monitoring to the trial team.
We will not deal here with the tricky statistical issues
of identifying outliers.6–9 The aim of the trial statistician,
however, would be to identify clinicians or centres that
lie outside the bounds of acceptable practice—those
who are in a different division, not just bottom of their
league. But when such a clinician is identified what
should happen?
Action on poor performance
The responsibility to future patients, who might be
harmed by a particular clinician, trumps all others. The
Department of Health guidance states: “The dignity,
rights, well being and safety of participants must be the
primary consideration in any research study.”1 Thus,
not only must the clinician’s participation in the trial be
suspended, but the person responsible for clinical gov›
ernance in that clinician’s healthcare organisation must
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be informed. The organisation’s usual response might
be to offer retraining to the clinician.
However, three further issues arise.
Firstly, we need to consider the welfare (particularly
the anonymity) of collaborating clinicians who take part
in trials. It would not be in the public interest if clinicians
declined to take part in studies for fear that they might
“incriminate” themselves.10 The anonymity of clinicians
should therefore be respected even though their use of
particular procedures is suspended. Since the purpose
of the trial is to influence practice at large, trial
procedures should follow routine practice as closely as
possible. If we assume regular audit of results under
clinical governance, then suboptimal performance in
daily practice will be detected, and the consequences
should be similar to those that occur in a trial—namely,
suspension of activity pending retraining. (Detection of
poor performance in routine post›trial practice would,
of course, be facilitated by the availability of “bench›
mark” results from preceding trials.)
Secondly, a methodological issue arises if the data
from one clinician is effectively censored. We advocate
that the data accrued by the clinician should be
included up to the point when he or she was
suspended from the trial.
The third issue to consider is whether there is a
duty to inform patients who have already suffered
complications and who were under the care of a clini›
cian subsequently found to have substandard results. If
there is such a duty then it conflicts with the obligation
to protect clinicians’ anonymity. There are strong argu›
ments against the routine feedback of individual
performance to past patients, which include the
creation of perverse incentives (for example, an incen›
tive to treat only patients likely to have good outcomes)
and the limited likelihood of net benefit from such
retrospective disclosure. Nevertheless, however society
decides to handle this issue, we think that trial practice
should mirror routine practice.
Next steps
Following a reasonable public debate, we suggest that
guidelines should be promulgated by organisations
responsible for scientific governance. Such guidelines
should state precisely who is responsible for doing
what—for example, the trial statistician could be
responsible for identifying “outliers,” the data monitor›
ing and ethics committee11 for ratifying conclusions,
and the trial steering committee for informing the rel›
evant health service organisation, which in turn would
be responsible for retraining. Secondly, clinicians and
those responsible for clinical governance should know
in advance that the outcomes of individual clinicians
will be analysed as a trial goes on, and they should be
aware of their rights and responsibilities if problems
arise, so that they are not ambushed by the process.
Patients should also be told what would happen if their
centre or clinician turned out to have suboptimal
results—for example, the circumstances under which
this would or would not be divulged.
We thank Professor Treasure and Dr Elizabeth Clough for
helpful comments.
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Commentary: Of course patients should be told
Heather Goodare
Clinical trials have been proclaimed to be good for you
on the grounds that patients in trials are “likely to be
treated to the highest possible standards”1—with the
implication that those not in trials are not. If this is true
it is worrying. But is it true? Do such patients really do
better?2 In some cases trials may actually damage your
health.
My own experience of a clinical trial, the notorious
Bristol study,3 was not a happy one,4 and I have since
observed suboptimal practice in seeking patients’ con›
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sent for trials, where the benefits are exaggerated and
the risks downplayed. In one case the protocol for a
multicentre chemotherapy trial had not even been
submitted to the local research ethics committee, with
unfortunate consequences. The local clinician had
strayed from the protocol, omitting the assessment of
quality of life, and there were other serious problems.
Careful audit by the trial team, as envisaged by Mason
and colleagues, would eventually have picked this up.
The authors seem to be more concerned with
surgical practice, where skill is of the essence, than with
drug treatments. Certainly, patients would want to
know if their surgeon was found to have a consistently
poor record. But we need to think of other common
problems in medical research that statistical monitor›
ing may well uncover. Outliers should not be the only
concern. What about deliberate fraud? Statisticians
should also be suspicious if one clinician’s results are
too good to be true, or too similar. There are many
examples, such as the returned packs of topical cream
in which the tubes had all been squeezed in exactly the
same way (FO Wells, Joint Consensus Conference on
Misconduct in Biomedical Research, London, 2000).
So if dubious practice is uncovered, should patients
be told? The authors distinguish between present and
future patients, but some patients survive for a long
time after treatment. The Bristol women fought their
own battle (one that statisticians should certainly have
anticipated as the purported results were wildly
improbable). Who is to speak up for truth, honesty, and
integrity when trialists veil their errors under a cloak of
confidentiality? This will only lead to further mistrust
of medical research. Patients and their relatives are
more robust than doctors might think. They are used
to hearing bad news: but the telling of it has to be done
with care and sensitivity.
1 Tobias J. Cancer: what every patient needs to know. London: Bloomsbury,
1995:63›72.
2 Bydder S. It needs to be established whether patients really fare better in
trials. BMJ 2000;321:1530›1.
3 Bagenal FS, Easton DF, Harris E, Chilvers CED, McElwain TJ. Survival of
patients with breast cancer attending Bristol Cancer Help Centre. Lancet
1990;336:606›10.
4 Goodare H,ed. Fighting spirit: the stories of women in the Bristol breast cancer
survey. London: Scarlet Press, 1996.
Commentary: The surgeon is only one factor
Tom Treasure
Patients deserve safety but it is disingenuous to link trials
with risk rather than benefit. Patients within trials have
better outcomes1 and it is arguable that trials are safer
than routine care. Safety requires an amalgam of clinical
judgment, attention to detail, commitment, care, techni›
cal skill, and the close monitoring of performance. These
attributes are as likely to be found among doctors doing
research as among those who are not. If we are to recruit
patients to trials they must believe (with justification) that
we will take good care of them. Monitoring of individual
performance will help to ensure that.
There is precedent for trial monitors to be the first
to identify poor technical results. In the first of the cor›
onary surgery multicentre trials there was a high mor›
tality in 1970›2, which was noted and documented.2
Simply archiving adverse data is not acceptable, but the
statistical significance of outliers remains problematic
when individual numbers are small. An extreme but
real example is a trial of multimodality treatment of
superior sulcus lung cancer in which 111 patients were
operated on by 76 different thoracic surgeons, a
median of one operation per surgeon.3 If we were to
take the unreasonable step of attributing the outcome
to the surgeon alone, most surgeons had 0% mortality
but, of course, a few had 100%.
A specific problem taxing us now is recruiting
patients into the MRC LU22 trial of induction chemo›
therapy for operable lung cancer. Persuasive evidence
(short of proof) suggests that outcomes would be better
if lung resection were preceded by chemotherapy, but
there is the fear that the cancer will progress during the
delay or that chemotherapy will increase the patient’s
vulnerability. Nothing but a randomised trial can
resolve this issue, but surgeons, ever conscious of peri›
operative safety, are wary. Personally I would like every
patient considered for multimodality cancer treatment
to be within a randomised trial because the issues are
far too complex and interwoven for any clinician to
rely on experience, clinical judgment, or “what works
best in my hands.” Without trials we will continue to
trade anecdotes and uncontrolled retrospective clinical
series that pass for research. We are woefully
inadequate in the care of lung cancer4 and every
operation outside a trial is data lost forever.
When trials involve skilled interventions such as sur›
gery it is appropriate to check the track record of the cli›
nicians taking part against explicit criteria. This has been
done in trials of the technically exacting procedures on
the carotid arteries,5 but clusters of poor outcomes in
multimodality cancer trials are not necessarily attribut›
able to the operating surgeon They are as likely to be
due to preoperative assessment, anaesthesia, drug errors
and side effects, and postoperative care. Surgical compe›
tence is part of the whole treatment package and should
be documented along with everything else. But we also
should remember that for the big three operations (in
terms of volume)—cataract surgery, hip replacement,
and coronary bypass operations—success relies on their
reproducibility in the hands of many competent and
committed surgeons—on whom every complication or
death weighs heavily. I do not mind whether it is trusts or
trialists who monitor standards as long as they do it fairly
and competently.
1 Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials
good for us (in the short term)? Evidence for a “trial effect.” J Clin Epide›
miol 2001;54:217›24.
2 Hampton JR. Coronary artery bypass grafting for the reduction of mor›
tality: an analysis of the trials. BMJ 1984;289:1166›70.
3 Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Johnson D, et al.
Induction chemoradiation and surgical resection for non›small cell lung
carcinomas of the superior sulcus: Initial results of Southwest Oncology
Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg
2001;121:472›83.
4 Does lung cancer need a lapel ribbon? Lancet 2000;356:1205.
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